Ultragenyx Pharmaceutical

Activities: Research & Development Pharmaceutical

Trending Articles

  1. IMed Consultancy helps Toby Orthopaedics navigate UK regulations Regulatory consultancy ensures compliance and confidence for Miami-based company
  2. Sanofi invests €40m into biopharmaceutical manufacturing at its Lyon Gerland site The pharma giant has expanded its French monoclonal antibody production capabilities, while also dedicating €25m to the development of a second-gen polyclonal antibody
  3. Samsung Biologics bags $668 manufacturing deal with European pharmaceutical company The CDMO will be responsible for the manufacture of the client's biopharmaceuticals until December 2031
  4. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance
  5. Sartorius Stedim Biotech supports bioprocess development with new Innovation Centre The Massachusetts, US-based Centre for Bioprocess Innovation is a collaborative space designed to develop and optimise biomanufacturing processes

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

Related Content

Regulatory

Ultragenyx and Kyowa Kirin announce MAA for KRN23 accepted for review by EMA

Ultragenyx Pharmaceutical and Kyowa Kirin International, a wholly owned subsidiary of Kyowa Hakko Kirin, has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application (MAA) for KRN23 for the treatment of X-linked hypophosphatemia (XLH)
Subscribe now